HRP20140785T1 - Kombinacijski pripravak, koji kao aktivni sastojak sadrži l-karnitin ili pripionil-l-karnitin, namijenjen sprjeäśavanju ili lijeäśenju kroniäśne venske insuficijencije - Google Patents
Kombinacijski pripravak, koji kao aktivni sastojak sadrži l-karnitin ili pripionil-l-karnitin, namijenjen sprjeäśavanju ili lijeäśenju kroniäśne venske insuficijencije Download PDFInfo
- Publication number
- HRP20140785T1 HRP20140785T1 HRP20140785AT HRP20140785T HRP20140785T1 HR P20140785 T1 HRP20140785 T1 HR P20140785T1 HR P20140785A T HRP20140785A T HR P20140785AT HR P20140785 T HRP20140785 T HR P20140785T HR P20140785 T1 HRP20140785 T1 HR P20140785T1
- Authority
- HR
- Croatia
- Prior art keywords
- carnitine
- acid
- propionyl
- combination preparation
- dose
- Prior art date
Links
- 229960001518 levocarnitine Drugs 0.000 title claims 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims 4
- 239000004480 active ingredient Substances 0.000 title claims 3
- 230000002265 prevention Effects 0.000 title claims 3
- 201000002816 chronic venous insufficiency Diseases 0.000 title claims 2
- 201000002282 venous insufficiency Diseases 0.000 title claims 2
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 claims 9
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims 6
- 208000020854 vein disease Diseases 0.000 claims 5
- 229960004203 carnitine Drugs 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims 3
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 claims 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims 3
- 229960004352 diosmin Drugs 0.000 claims 3
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 claims 3
- 229940025878 hesperidin Drugs 0.000 claims 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229960003232 troxerutin Drugs 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 229940009098 aspartate Drugs 0.000 claims 2
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- -1 pamoate Substances 0.000 claims 2
- 208000001297 phlebitis Diseases 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- 230000036269 ulceration Effects 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010023232 Joint swelling Diseases 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000005515 coenzyme Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229940095060 magnesium tartrate Drugs 0.000 claims 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940066528 trichloroacetate Drugs 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Kombinacijski pripravak, naznačen time što kao aktivne sastojke sadrži l-karnitin ili propionil-1-karnitin, ili njegovu sol, trokserutin, diosmin, hesperidin, te izborno jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
2. Kombinacijski pripravak u skladu s patentnim zahtjevom 1, naznačen time što sadrži:
– l-karnitin ili propionil-1-karnitin, u dozi od 10 do 3000 mg, gdje se poželjne doze kreću od 50 mg do 400 mg, a najpoželjnija doza je 136 mg;
– trokserutin, u dozi od 900 mg do 50 mg, gdje se poželjne doze kreću od 400 mg do 200 mg, a najpoželjnija doza je 300 mg;
– diosmin, u dozi od 900 mg do 50 mg, gdje se poželjne doze kreću od 400 mg do 200 mg, a najpoželjnija doza je 300 mg; i
– hesperidinu dozi od 10 mg do 500 mg, gdje se poželjne doze kreću od 50 mg do 200 mg, a najpoželjnija doza je 100 mg.
3. Kombinacijski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se upotrebljava kao dodatak ishrani.
4. Kombinacijski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se upotrebljava kao medikament.
5. Kombinacijski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži koenzime, mineralne tvari, antioksidanse, vitamine, sredstva protiv zgrušavanja, te sredstva korisna u liječenju bolesti vena.
6. Kombinacijski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju bolesti vena.
7. Upotreba kombinacijskog pripravka koji kao aktivne sastojke sadrži l-karnitin ili propionil-1-karnitin, ili njegovu sol, trokserutin, diosmin i hesperidin, naznačen time što je namijenjen pripravi medikamenta za sprječavanje ili liječenje bolesti vena.
8. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što se bolest vena bira iz skupine koju čine: kronična venska insuficijencija, kronična bolest vena i njezina komplikacija.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što se navedenu komplikaciju bira iz skupine koju čine: oteklina i upala vena u rektumu, anusu i vulvi; venska hipertenzija; povećana propusnost; edem; oštećenje kapilara; promjene na koži; ulceracije vena na nogama; otečeni gležnjevi; teške noge; varikozne vene; otečene noge; ulceracije; venska tromboza; flebitis; tromboflebitis; plućni embolus ili hemoroidi.
10. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što se sol l-karnitina ili propionil-1-karnitina bira iz skupine koju čine: klorid, bromid, orotat, aspartat, kiseli aspartat, kiseli citrat, magnezijev citrat, fosfat, kiseli fosfat, fumarat i kiseli fumarat, magnezijev fumarat, laktat, maleat i kiseli maleat, oksalat, kiseli oksalat, pamoat, kiseli pamoat, sulfat, kiseli sulfat, glukozni fosfat, tartarat i kiseli tartarat, glicerofosfat, mukat, magnezijev tartarat, 2-aminoetansulfonat, magnezijev 2-aminoetansulfonat, metansulfonat, kolin-tartarat, trikloracetat ili trifluoracetat.
11. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što je namijenjena oralnoj, parenteralnoj, intravenskoj, topikalnoj i/ili transdermalnoj primjeni.
12. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što je namijenjena oralnoj primjeni.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10152363A EP2353596A1 (en) | 2010-02-02 | 2010-02-02 | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency |
| US32253210P | 2010-04-09 | 2010-04-09 | |
| PCT/IB2011/000200 WO2011095882A1 (en) | 2010-02-02 | 2011-02-07 | Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140785T1 true HRP20140785T1 (hr) | 2014-11-07 |
Family
ID=51844410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140785AT HRP20140785T1 (hr) | 2010-02-02 | 2014-08-20 | Kombinacijski pripravak, koji kao aktivni sastojak sadrži l-karnitin ili pripionil-l-karnitin, namijenjen sprjeäśavanju ili lijeäśenju kroniäśne venske insuficijencije |
Country Status (6)
| Country | Link |
|---|---|
| CA (1) | CA2787470C (hr) |
| CL (1) | CL2012001740A1 (hr) |
| HR (1) | HRP20140785T1 (hr) |
| MY (1) | MY182607A (hr) |
| SM (1) | SMT201400121B (hr) |
| ZA (1) | ZA201206518B (hr) |
-
2011
- 2011-02-07 CA CA2787470A patent/CA2787470C/en not_active Expired - Fee Related
- 2011-02-07 MY MYPI2012002962A patent/MY182607A/en unknown
-
2012
- 2012-06-25 CL CL2012001740A patent/CL2012001740A1/es unknown
- 2012-08-30 ZA ZA2012/06518A patent/ZA201206518B/en unknown
-
2014
- 2014-08-20 HR HRP20140785AT patent/HRP20140785T1/hr unknown
- 2014-09-01 SM SM201400121T patent/SMT201400121B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2787470A1 (en) | 2011-08-11 |
| CA2787470C (en) | 2018-03-27 |
| CL2012001740A1 (es) | 2012-11-09 |
| MY182607A (en) | 2021-01-26 |
| SMT201400121B (it) | 2014-11-10 |
| ZA201206518B (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019203820B2 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
| ES2606392T3 (es) | Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas | |
| JP6657394B2 (ja) | ざ瘡の予防および治療のためのタウリンおよびマグネシウムを含む局所用製剤および経口用製剤 | |
| ES2466318T3 (es) | Composición farmacéutica que comprende la combinación de diversos agentes venotónicos y vasoprotectores para el tratamiento de la insuficiencia venosa crónica | |
| ES2487647T3 (es) | Composición de combinación que comprende, como ingrediente activo, L-carnitina o propionil-L-carnitina, para la prevención o el tratamiento de la insuficiencia venosa crónica | |
| KR20110083628A (ko) | 셀룰라이트의 치료에 유용한 화합물 | |
| JP2006506361A5 (hr) | ||
| HRP20140785T1 (hr) | Kombinacijski pripravak, koji kao aktivni sastojak sadrži l-karnitin ili pripionil-l-karnitin, namijenjen sprjeäśavanju ili lijeäśenju kroniäśne venske insuficijencije | |
| US20040048914A1 (en) | Composition and method for treating skin | |
| JP2013523603A5 (hr) | ||
| US11642328B2 (en) | Creatine, its derivatives, compositions and methods of use thereof | |
| JP2013523603A (ja) | 活性成分としてｌ−カルニチンまたはプロピオニルｌ−カルニチンを含む慢性静脈不全の予防または治療のための併用組成物 | |
| RU2021108388A (ru) | Железосодержащая композиция и ее применение | |
| CN106572969A (zh) | 用于治疗银屑病的药物组合物 | |
| KR20240062990A (ko) | 부상 및/또는 피부 병태의 치료를 위한 조성물 및 방법 | |
| AU2018279043A1 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
| Trivedi | Role of cranberry juice in preventing recurrent urinary tract infections in the pediatric population | |
| JP2020528462A (ja) | 片頭痛の予防及び治療に使用するための栄養補助食品 | |
| Srinivas | Eyeing opthalmic products: Bioequivalence assessment and drug development-Strategic considerations | |
| RU2017105074A (ru) | Комбинация адапалена и бензоилпероксида для лечения тяжелой формы акне | |
| FR2967352B1 (fr) | Comprime effervescent pour l'administration par voie orale de principes actifs |